Saeed Sadeghi, MD, discusses treatment options in low-risk myelodysplastic syndrome at a Case-Based Roundtable event.

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are ...

Akebia Therapeutics is currently shifting focus from Auryxia to Vafseo due to Auryxia’s declining revenues. See why I ...

The only way to keep your kidney functions intact is by ensuring you drink plenty of fluids. Here are 7 best detox drinks ...

Erythropoiesis is the process by which red blood cells (erythrocytes) are produced. During human foetal development, erythropoiesis first occurs in the yolk sac, then in the foetal liver and then ...

Hypoxia, a condition characterized by reduced oxygen availability, has been widely studied for its potential therapeutic ...

Bitopertin is an investigational agent and is not approved for use as a therapy in any jurisdiction worldwide. Disc obtained global rights to bitopertin under a license agreement from Roche in May ...

Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report) and keeping the price target at ...

Non-transfusion-dependent thalassemia encompasses three clinically distinct forms -- beta-thalassaemia intermedia, hemoglobin E/beta-thalassaemia (mild and moderate forms), and al ...

Myelodysplastic syndromes (MDS) are marked by ineffective hematopoiesis and dysplasia, which elevate the risk of progression to acute myeloid leukemia (AML). The inflammatory environment in MDS alters ...

O n Friday, H.C. Wainwright reiterated its Buy rating and $7.50 price target for Akebia Therapeutics (NASDAQ:AKBA) stock, which is currently trading near its 52-week high of $2.48 and has shown ...